Controversial data on sarcosine as a promising biomarker for prostate cancer (PCa) detection are present. The objective was to clarify these discrepancies and reevaluate the potential value of sarcosine in PCa. Sarcosine algorithms (supernatant and sediment sarcosine/creatinine, supernatant and sediment log2 (sarcosine/alanine)) in urine samples from 71 untreated patients with PCa, 39 patients with no evidence of malignancy (NEM) and 20 healthy women and men were quantified by liquid chromatography/tandem mass spectrometry. Although any sarcosine algorithms were significantly higher in PCa patients than in NEM patients (all Po0.05), comparable sarcosine values were measured in healthy women and men. Additionally, neither biopsy Gleason score nor clinical T-stage were correlated with sarcosine algorithms (all P40.05), and receiver operating characteristic curve analysis indicated that the diagnostic power of any of sarcosine algorithms was nonsignificantly higher than that of serum and urine PSA, but nonsignificantly lower than prostate cancer antigen 3 (PCA3) and the percent-free PSA (%fPSA). Improved diagnostic performances were observed when any of sarcosine algorithms was combined with PCA3 or %fPSA. In conclusion, the predictive power of sarcosine in PCa is modest compared with PCA3 and %fPSA. Sarcosine, which awaits more validation before it reaches the clinic, could be included into the list of candidate PCa biomarkers.
Introduction
Prostate cancer (PCa) is one of the most commonly diagnosed malignancies, and is the second leading cause of cancer-related deaths in the Western male population. 1 In China, the detection rate of PCa is increasing rapidly because of the extension of life expectancy, the change of lifestyles and the improvement of clinical skills. 2 Subsequently, conquering this stubborn disease has significant effect on the improvement of the health of the global male population. On the basis of individual metabolites representing end points of the molecular pathways perturbed by events in the genome, transcriptome or proteome, newly emerging metabolite profile or metabolomics shows potential to monitor metabolite changes that characterize abnormal processes occurring in the progression of disease and might provide clues for the treatment and diagnosis of disease. 3, 4 To the best of our knowledge, metabolomic analysis has already been used for identifying metabolic markers in tumors. [5] [6] [7] Notably, Sreekumar et al. 8 demonstrated that sarcosine can be used as a biomarker for PCa and was non-invasively detected in urine, which led to great interest in the scientific community and among potential PCa patients. However, the first independent validation study 9 showed that sarcosine cannot be used as a biomarker to diagnose PCa and predict its aggression. Following these observations, letters and replies [10] [11] [12] [13] [14] [15] [16] were published to discuss potential reasons for the contradictions between these two studies. 8, 9 Although many possibilities (for example, the analytical method, the biomarker assay, the comparators and the study cohort) were discussed; no data from complete article has been reported.
In this report, we sought to use liquid chromatography/tandem mass spectrometry, compare log2 (sarcosine/alanine) and sarcosine/creatinine in both urinary supernatant and sediment and use prostate cancer antigen 3 (PCA3) and the percent-free PSA (%fPSA) as comparators to determine whether sarcosine has the potential role in PCa diagnostics and prognostics.
Materials and methods

Specimen source, collection and processing
This study was carried out according to the institutional review board-approved study protocol. Written in-formed consent for each study participant was also obtained. Between February and August 2010, a total of 110 consecutive patients with PSA44 ng ml À1 or abnormal digital rectal examination, out of which 71 patients with PCa and 39 patients with no evidence of malignancy (NEM), as confirmed by 10 core prostate biopsy samples at Shanghai Cancer Center (Shanghai, China), were enrolled. At the time of enrollment and at 1 week later, the first-void urines from these 110 patients were collected, respectively, after standardized digital rectal examination 17 in about 5 min. The second-morning void urines from 20 healthy men and women were also obtained. In addition, clinicopathological features of all patients investigated were recorded and presented in Table 1 .
Following collection, 40-50 ml urine sample was cooled immediately on ice and centrifuged at 4 1C and at 700 g for 10min within 1h. Upon centrifugation, the first urinary sediment collected at the time of enrollment was mixed with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) to measure PSA mRNA and PCA3; the second urinary sediment collected at 1 week later was added to 5 ml of 1 M boric acid to analyze sarcosine, and urinary supernatant was also collected to analyze sarcosine. After treatment, these samples were stored at À80 1C until analysis.
Determination of sarcosine, alanine, creatinine and other analytes
Sarcosine and alanine were derivatized and isolated using propyl chloroformate, and measured using a Shimadzu LC-20AD UFLC system (Shimadzu, Kyoto, Japan) in conjunction with an 3200 QTrap mass spectrometry (Applied Biosystems, Carlsbad, CA, USA) as previously described. 18 Urinary creatinine concentrations were measured by a standard assay on the Hitachi 7020 analyzer (Hitachi, Tokyo, Japan). These results obtained were then used to calculate four kinds of sarcosine algorithms (supernatant and sediment sarcosine/creatinine, supernatant and sediment log2 (sarcosine/alanine)). The expression levels of PSA mRNA and PCA3 were determined as previously described. 18 
Statistical analysis
Statistical analyses were performed using the R software (The University of Auckland, Auckland, New Zealand) and SPSS 17.0 (SPSS, Chicago, IL, USA). As only subjects with PSA o20 ng ml À1 were included in the study by Jentzmik et al., 9 patients in this study were divided into a subgroup of all patients and a subgroup of patients with PSA o20 ng ml À1 to facilitate comparison. Independent sample t-test or Mann-Whitney's U-test was used to compare differences between two sets of continuous variables, and Fisher's exact test for the analysis of n Â n tables. Spearman's or Pearson's rank correlation and linear regression analysis were performed to determine the relationships between clinicopathological features and any of sarcosine algorithms. Logistic regression analysis was used to analyze correlation between PCa diagnostic status and tested marker. Diagnostic performance of investigated marker was Efforts to solve controversy in sarcosine D-L Cao et al evaluated using the receiver operating characteristic curve analysis, and the overfitting bias for the area under curve (AUC) calculations was estimated using special bootstrap software. A two-tailed P-value o0.05 was considered statistically significant.
Results
As shown in Table 1 , equalities regarding clinicopathological characteristics of patients were estimated and no significant differences were found except for %fPSA, both in all patients and patients with PSA o20 ng ml
À1
. With regard to sarcosine/creatinine and log2 (sarcosine/alanine) in urinary supernatant from all patients, there were no differences among healthy female, healthy male and NEM patients (Figures 1a and d) . In the cohort of all patients, any of sarcosine algorithms was significantly higher in PCa than in NEM patients (Figures 1a  and d ), but no significant differences in both creatinine and alanine levels in urinary supernatant and sediment were found between patients with PCa and NEM (Supplementary Figure 1) , indicating that they would not influence the proper evaluation about the role of sarcosine in PCa. Our study also showed that neither biopsy Gleason score nor clinical T-stage (cT stage) were correlated with any of sarcosine algorithms in all patients (Figures 1b-c, e-f). It is to be noted that patients with PSA o20 ng ml À1 held similar features as mentioned above for the subgroup of all patients (data not shown). Not only in the cohort of all patients but also in the cohort of patients with PSA o20 ng ml À1 , there was no significant difference between supernatant sarcosine/ creatinine and sediment sarcosine/creatinine in the subgroup of NEM patients, PCa patients, Gleason score o7 patients, Gleason scoreX7 patients, cT stage o2b patients or cT stageX2b patients (all P40.05); the same is true for the comparison between supernatant and sediment log2 (sarcosine/alanine) levels (all P40.05).
The diagnostic performances of tested variables were summarized in Table 2 . Numerically, the AUCs for four kinds of sarcosine algorithms were nonsignificantly higher than those for serum PSA and urine PSA mRNA, but nonsignificantly lower than those for PCA3 and %fPSA in both cohorts. Specifically, the diagnostic power of sediment log2 (sarcosine/alanine), with the highest AUC among the four kinds of sarcosine values, was not significantly better than that of serum PSA, both in all patients (P ¼ 0.219) and in patients with PSA o20 ng ml À1 (P ¼ 0.063). Nevertheless, including any of sarcosine algorithms in multivariate logistic regression models with PCA3 or %fPSA could improve the AUC relative to the single biomarkers in both groups (Table 2 ). After correcting the potential over-fit for initial AUCs for investigated variables, using specific bootstrap software, which consequently generated matched unbiased AUCs, differences between initial AUCs and matched unbiased AUCs were estimated to be small and can be neglected (Table 2) . By Pearson and Spearman correlation analysis, we observed that significant relationships were detected among four kinds of sarcosine algorithms, both in all patients and patients with PSA o20 ng ml À1 , except for supernatant sarcosine/creatinine versus supernatant log2 (sarcosine/alanine), supernatant sarcosine/creatinine versus sediment log2 (sarcosine/alanine), sediment sarcosine/creatinine versus supernatant log2 (sarcosine/ alanine) and sediment sarcosine/creatinine versus sediment log2 (sarcosine/alanine) in patients with NEM in both cohorts (Table 3) . Additionally, both in the population of all patients and patients with PSA o20 ng ml À1 , age, serum PSA, prostate volume, urine PSA mRNA, %fPSA and PCA3 did not correlate with any of sarcosine algorithms in any of the two subgroups (patients with PCa and patients with NEM), with the exception of PCA3 versus supernatant and sediment log2 (sarcosine/ alanine) in patients with PCa in the first cohort, and serum PSA versus supernatant and sediment log2 (sarcosine/alanine), urine PSA mRNA versus sediment sarcosine/creatinine and PCA3 versus supernatant and sediment log2 (sarcosine/alanine) in patients with PCa in the second cohort (Supplementary Table 1) .
As the range of 2.5-10 ng ml À1 is considered to be the clinically challenging value for PSA, we have also evaluated the potential role of any of sarcosine algorithms in the subset of patients having PSA 2.5-10 ng ml À1 and found that the role of any of sarcosine algorithms in the subset of patients with PSA between 2.5 and 10 ng ml À1 were similar to those in the subsets of all patients and patients with PSA o20 ng ml À1 (data not shown).
Discussion
The present study validated some reasons for the discrepancies on sarcosine as a promising biomarker for PCa and subsequently reevaluated the potential role of urinary sarcosine in PCa detection and prognosis.
Metabolomics, an omics science in systems biology, is the globally quantitative assessment of endogenous metabolites within a biological system and allows for a comprehensive evaluation of a cellular state within the context of the immediate environment, taking into account genetic regulation, altered kinetic activity of enzymes and changes in metabolic reactions. 4, 19, 20 Importantly, the tumor metabolome is generally characterized by increased phospholipid levels, elevated glycolytic capacity, high glutaminolytic function and overexpression of the glycolytic isoenzyme (pyruvate kinase type M2, M2-PK), as previously reviewed. 3 With regard to the application of metabolomics in cancer diagnostics, PCa demonstrated a different metabolic profile characterized by high glycolytic products, total choline-containing compounds and phosphocholine levels. 21 In addition, prostatic fluid from men with PCa, exhibited reduced citrate and increased spermine levels, which correlated well with Gleason score, and outperformed PSA in cancer diagnosis. 22, 23 Not limited to the field of PCa diagnosis, metabolomics is also providing essential information about tumorigenesis, cancer diagnosis in other tumors, cancer prognosis, therapeutic evaluation and revealing new therapeutic targets. 3, 4 These observations clearly showed that metabolomics have a significant role in providing a more comprehensive picture of tumor development.
Sarcosine is found naturally as an intermediate in the metabolism of choline and methionine, 24 and also generated by the enzymatic transfer of a methyl group from S-adenosylmethionine to glycine, and thus shows a substantial role in methyl balance in humans. 25 Interestingly, a recent report in Nature by Sreekumar et al. 8 demonstrated that sarcosine as one of metabolites offers a promising, non-invasive diagnostic and prognostic test for PCa. However, the first validation study 9 did not support that sarcosine has any advantage over serum PSA, %fPSA, Gleason score and tumor stage. Obviously, it will be of great importance to clarify these contradictions regarding sarcosine as a promising test for PCa in greater details. Abbreviations: '+', combined with; %fPSA, the percent ratio of free to total PSA; AUC, area under the ROC curve; CI, confidence interval; PCA3, prostate cancer antigen 3; ROC, receiver operating characteristic; S/A, sarcosine/alanine ratio; S/C, sarcosine/creatinine ratio.
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In this study, any of sarcosine algorithms was significantly higher in PCa than in NEM patients not only in all patients (Figures 1a and d) but also in patients with PSA o20 ng ml À1 (data not shown), supporting the report by Sreekumar et al. 8 and simultaneously opposing the study by Jentzmik et al. 9 As urinary creatinine concentration of patients with NEM did not differ from that of PCa patients in both groups ( Supplementary  Figure 1) , the creatinine normalization could not be the reason for this contradictory result. These inconsistent results might be explained by differences between the study populations or in pathological evaluation of specimens. For example, a fair comparison between urinary sarcosine and serum PSA would be the one in which asymptomatic men aged 50-70 years were screened by each method, followed by prostate biopsy of the men with positive screening results, and calculation of diagnostic sensitivities and specificities. Importantly, comparable sarcosine values were detected in healthy women and men and no significant differences among healthy females, males and NEM patients were found as listed in our results, indicating that sarcosine could not be used as a promising biomarker for PCa. In addition, no significant differences between urinary supernatant and sediment sarcosine levels as described in our results (all Po0.05) illustrated that digital rectal examination did not significantly change urinary sarcosine levels, which would generate a concept that sarcosine as a small metabolite is rapidly released into the urinary supernatant.
Furthermore, any of sarcosine algorithms was independent of biopsy Gleason score and cT stage, both in all patients (Figures 1b-c, e-f ) and in patients with PSA o20 ng ml À1 (data not shown), these observations were similar to previous studies. 8, 9 Comparing with Gleason score and T stage, determined in radical prostatectomy tissue specimens, the fact that PCa is heterogeneous disease and thus results in underestimating biopsy Gleason score and cT stage, might explain the above mentioned issue. Follow-up data on the final Gleason score and T stage after radical prostatectomy will clarify in time whether sarcosine excretion has association with Gleason score and T stage. Our study also demonstrated that the AUC for any of sarcosine algorithms was nonsignificantly higher than that for serum PSA and urine PSA mRNA, but nonsignificantly lower than that for PCA3 and %fPSA, in both population (Table 2) , which basically was consistent with data obtained from Sreekumar et al. 8 and Jentzmik et al. 9 It is to be noted that improved AUCs were obtained when any of sarcosine values was combined with PCA3 or %fPSA (Table 2) , which could support the speculation that adding sarcosine to a panel has the potential to increase the accuracy of diagnosing PCa.
The limitations of the present study have been addressed as follows. First, cancer patients were enriched during sample collection process to generate subsequent robust data analysis, which resulted in the study population that does not represent those in the everyday clinical practice. As explained by Jentzmik et al., 9 the risk of type II error could be eliminated and a screening population would probably not change the data. In addition, bias may be generated from the retrospective design, but the recent study mainly used one of the retrospective designs, also named as nested Table 3 Correlative associations among sarcosine algorithms PSA range (ng ml Efforts to solve controversy in sarcosine D-L Cao et al case-control design, by which urine specimens were collected from patients with PSA44 ng ml À1 or abnormal digital rectal examination before prostate biopsy and later undergone retrospective evaluation, which can help minimize the problem of baseline inequality because the presence and absence of disease cannot affect selection of subjects or handling of specimens. Although metabolites (for example, sarcosine) in metabolomic profile could fluctuate markedly depending on differently physiological and pathological state, the validity of our data could be guaranteed by the use of nested case-control design and sophisticated liquid chromatography/tandem mass spectrometry technology. Along with sound design of study, technical progress, establishment of database and accumulation of evidences, it can be increasingly believed that effectively controlled bias could not change the results, and the metabolomics would be a good source of biomarkers for diagnostics and prognostics.
Conclusion
In summary, the present study demonstrated that the predictive power of sarcosine in PCa is modest compared with PCA3 and %fPSA. Although cancer-related metabolomics has a substantial role in providing a more comprehensive picture of tumor development, metabolomic profile could fluctuate markedly depending on different status and thus the data for metabolites (for example, sarcosine) should be interpreted with caution before increased understanding of metabolomics are obtained. The sarcosine pathway might provide clues for PCa diagnosis or progression, while sarcosine that awaits more validation, before it contributes to clinical decision making, could be included into the long list of candidate PCa biomarkers.
